BioInvent International (BINV) Jefferies Global Healthcare Conference 2026 summary

Strategic positioning and platform capabilities

• Integrated operations in Sweden with in-house target discovery, manufacturing, and clinical development.

• Focus on immune oncology, addressing the immunosuppressive tumor microenvironment as a key bottleneck.

• Two first-in-class immuno-oncology programs with strong efficacy and safety in both solid and liquid tumors.

• International shareholder base with over 50% ownership by major global investors.

BI-1808 (TNFR2) program highlights

• Demonstrated robust single-agent and combination activity in advanced ovarian cancer and T-cell lymphoma.

• Combination with pembrolizumab achieved a 24% overall response rate and 56% disease control rate in ovarian cancer, with a progression-free survival of 10.3 months.

• Strong safety profile enables use in combination regimens and potential for earlier lines of therapy.

• Ongoing phase II studies in ovarian cancer and T-cell lymphoma, with Fast Track and Orphan Drug designations secured.

• Plans to seek pivotal study readiness and regulatory designations by year-end.

BI-1206 (FcγRIIB) program highlights

• Targets resistance to anti-CD20 therapy in non-Hodgkin lymphoma, with 80% ORR and 100% disease control rate.

• Subcutaneous formulation offers convenience and low toxicity, suitable for elderly and frail patients.

• Demonstrated long-lasting complete responses exceeding three years.

• Expanding into first-line non-small cell lung cancer and uveal melanoma, with promising early responses in heavily pretreated patients.

• First readouts for these indications expected in the second half of the year.